Search Immortality Topics:

Page 411«..1020..410411412413..420430..»


Category Archives: Stem Cell Therapy

International Stem Cell Corporation Comments on WSJ Article “Hope for Stem-Cell Treatment of Parkinson’s”

“Researchers have used stem cells obtained from human embryos to successfully treat Parkinson's disease in mice and rats, a key step in the quest to develop a similar approach for people.
In a study published Sunday in the journal Nature, scientists described how they converted human embryonic stem cells into nerve cells that produced the brain chemical dopamine. When these nerve cells were transplanted into the brains of mice and rats, they released dopamine and got rid of the animals' Parkinson's symptoms. The cells were also successfully transplanted into rhesus monkeys, whose biology is closer to that of humans.”
SOURCE - To read the complete article on The Wall Street Journal HEALTH site, please click HERE
Comments from International Stem Cell Corporation:

International Stem Cell Corporation (ISCO) announced in July 2011 the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells. The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSCs), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).

Dr. Andrey Semechkin, Co-Chairman and CEO of ISCO, comments: “The ability of neuronal cells to become a specific type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”


Forward-looking Statements
Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on International Stem Cell Corporation Comments on WSJ Article “Hope for Stem-Cell Treatment of Parkinson’s”

International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care

International Stem Cell Corporation (OTCBB:ISCO) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline's products in Australia and New Zealand under Lifeline's own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company's website http://www.lifelineskincare.com.

The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.

"I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report," said Dr. Keller. "Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they've seen are amazing."
Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: "Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.

"In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand."

Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin's own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20111110005408r1&sid=14230&distro=ftp
International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com

or
International Stem Cell Corporation
Donna Queen, Vice President of Marketing and Business Development
760-710-3295
dqueen@lifelineskincare.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

S
ource:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care

Searching for Facts About Cash: CIRM to Treasurer to Finance


"Even if your mother says it is true, check it out," an old saying goes. So we did.

The case in point was the new financial arrangement for the $3 billion California stem cell agency.

CIRM Chairman Jonathan Thomas laid out the plan last month for the California Stem Cell Report in the wake of a state bond issue that provided only $51 million for the agency, which fell far short of its needs over the next year or so. He said, however, a new arrangement was in place that amounted to a win-win for the state and the stem cell agency. The plan minimizes the amount of state bond borrowing immediately needed and instead provides, if necessary, short-term commercial paper, also backed by the state, but at less interest cost.

Thomas said both the state treasurer and the Brown Administration, through its state Department of Finance, were on board.

But -- keeping the admonition about mothers in mind -- we routinely asked the Finance Department and the state treasurer's office about the arrangement. What happened then provides some insight into how difficult it is sometimes to verify even what appear to be simple facts. It also tells a story about the responsiveness of state agencies and their dedication to openness and transparency.

Let's start with CIRM and Thomas. After we raised questions by email following the state bond sale Oct. 19, he offered a telephone interview about the situation and persisted despite dropped cellular signals and several callbacks from our post here in the bay off Panama City.

After we filed our item on the interview, we queried on Oct. 24 the other two agencies involved. The state treasurer's office responded quickly. The state Department of Finance, on the other hand, has remained silent on the subject to this day, despite three emailed queries.

Unfortunately, the state treasurer office's initial response was off the mark. "We haven’t seen any agreement.  We were not aware of the reported agreement until we read about it in your blog.  So, we have no comment about the reported agreement," the treasurer's office said initially.

That raised eyebrows a bit. So we renewed our queries to the Finance Department, even suggesting that a failure to respond could be construed as an indication that the Brown Administration is not fully behind CIRM.

Ten days after our initial query to the two agencies, we sent an email to Thomas briefly describing what we had planned to write and asking him if he would like to comment. He did not respond. But the next day, Steve Cooney, chief deputy state treasurer, said in an email that the earlier comment from the treasurer's office was incorrect. Cooney said,

"Our office DOES (Cooney's capitalization) and DID know that CIRM and the Department of Finance reached an understanding about future funding.

"The Treasurer’s Office has been aware since before last month’s sale of GO (general obligation) bonds that the Department of Finance and CIRM are in general agreement that the state will take necessary action to ensure that CIRM has adequate funds to meet its operational, grant funding and reserve needs, including the use of the state’s commercial paper line in the event the state cannot timely access the bond market.  It is neither necessary nor usual for our office to be informed of the specifics, if any, of any future commitment made by the Administration to any other state agency, including CIRM, and this case is no exception."

Cooney additionally re-affirmed the commercial paper arrangements for CIRM as laid out in the initial response from the treasurer's office.

The response said,

"The issuance of commercial paper has always been a part of our bond financing program.  The size of the CP line is about $1.5 billion, and it is available for use by all infrastructure programs, including stem cell research.  When we issue commercial paper to finance infrastructure projects, including CIRM, the paper is repaid with bond-sale proceeds.  So, if CIRM received funds from the issuance of commercial paper, the 'loan' would be retired not by CIRM, but by the proceeds of a subsequent bond sale."

Cooney also said,

"If you still need further clarification on the issue of future CIRM funding beyond the proceeds of the recent bond sale, the best place to get that information continues to be the Department of Finance."

Silence, however, has only been heard from the state Department of Finance.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on Searching for Facts About Cash: CIRM to Treasurer to Finance

Trounson, Parthenotes and International Stem Cell


The president of the California stem cell agency, Alan Trounson, popped up in a recent article in Scientific American dealing with a method for creating pluripotent stem cells from unfertilized human eggs.

The piece by Julia Galef said that "many investigators remain frustrated" that the method "remains offlimits" for federal funding, a barrier that does not apply to financing from the $3 billion California stem cell agency.

Galef wrote that one California firm, International Stem Cell Corp., of Carlsbad, is using the method to develop products. She said the firm's work involves "a process called parthenogenesis, in which researchers use chemicals to induce the egg to begin developing as if it had been fertilized. The egg—called a parthenote—behaves just like an embryo in the early stages of division. Because it contains no genetic material from a father, however, it cannot develop into a viable fetus."

Trounson was quoted as saying, nonetheless, that "proving that unfertilized eggs will produce stable tissues in humans remains an obstacle." He said other labs need to replicate the work.

International Stem Cell has applied unsuccessfully several times for research funding from the California stem cell agency.

The Scientific American article said,

"International Stem Cell scientists have converted them into liver cells and plan to convert them into neurons for treating Parkinson’s disease, pancreatic cells for diabetes, and other tissues. Meanwhile teams at the Massachusetts-based Bedford Stem Cell Research Foundation are working to improve the efficiency of methods of deriving stem cells from parthenotes."

As researcher interest in parthenotes gains attention, the NIH is being urged to change its negative position. Late last year, Teresa Woodruff, founder and director of the Institute for Women's Health Research at Northwestern University Feinberg School of Medicine, and others called for a lifting of the NIH ban on funding for parthenotes.

California is not constrained by NIH limitations. One of the key reasons, if not the only reason, that voters approved in 2004 the ballot initiative that created the $3 billion stem cell agency was to fund research that the federal government did not. At the time, the focus was on the Bush ban on financing hESC research.

Ken Aldrich, co-chairman of International Stem Cell, circulated the Scientific American article, touting its significance.

We found this posting on the Stem Cell Pioneers web site in which Aldrich said,

“We at International Stem Cell Corporation (ISCO.OB) are finding it increasingly gratifying that mainstream and highly respected publications like Scientific American are now beginning to take notice of the fact that our parthenogenetic stem cells may well turn out to be a viable alternative to the embryonic stem cells that have dominated research and headlines for the last 10 years.

"Like embryonic stem cells, our parthenogenetic stem cells can be converted into almost any kind of cell that might ever be needed for therapy, but can also provide a solution to the two biggest issues that have surrounded embryonic stem cell research: 1) the ethics of destroying a fertilized embryo, which our process never does, and 2) the problem of immune rejection by the patient. We hope you enjoy the attached article." 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy, Stem Cells | Comments Off on Trounson, Parthenotes and International Stem Cell

California Stem Cell Report Article: “Trounson, Parthenotes and International Stem Cell”

Source: http://californiastemcellreport.blogspot.com/2011/11/trounson-parthenotes-and-international.html

The president of the California Stem Cell Agency, Alan Trounson, popped up in a recent article in Scientific American dealing with a method for creating pluripotent stem cells from unfertilized human eggs. 

The piece by Julia Galef said that "many investigators remain frustrated" that the method "remains offlimits" for federal funding, a barrier that does not apply to financing from the $3 billion California stem cell agency. 

Galef wrote that one California firm, International Stem Cell Corp., of Carlsbad, is using the method to develop products. She said the firm's work involves "a process called parthenogenesis, in which researchers use chemicals to induce the egg to begin developing as if it had been fertilized. The egg—called a parthenote—behaves just like an embryo in the early stages of division. Because it contains no genetic material from a father, however, it cannot develop into a viable fetus." 

To read the complete article on "California Stem Cell Report", please click here  

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy | Comments Off on California Stem Cell Report Article: “Trounson, Parthenotes and International Stem Cell”

International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care

International Stem Cell Corporation (OTCBB:ISCO) today announced two new international marketing initiatives. The first is the successful conclusion of an agreement in principle to distribute its Lifeline Skin Care product line in the United Arab Emirates via a strategic relationship with noted facial plastic surgeon, Dr. Gregory S. Keller MD of Los Angeles and Santa Barbara, CA. The second is the engagement of Dr. K. McIsaac who will distribute Lifeline's products in Australia and New Zealand under Lifeline's own brand name. These agreements mark the first time that Lifeline Skin Care has distributed its products overseas. Currently, Lifeline Skin Care products are sold in the United States through the Company's website http://www.lifelineskincare.com.

The UAE represents an attractive market of some 4.3 million people, of which nearly 75% are expatriates. This cosmopolitan market is one of the most urbanized nations in the world with about 88% of its population living in cities. It has one of the highest per capita incomes in the world and an annual GDP growth rate at 8.8%.

"I am excited to introduce Lifeline Skin Care products to the UAE, and I am confident that our customers there will enjoy the same kind of satisfaction with the products as many of my patients in the United States report," said Dr. Keller. "Many of my American patients have been using these products since they were introduced on the market earlier this year, and the results they've seen are amazing."
Dr. Ruslan Semechkin, CEO of Lifeline Skin Care commented: "Dr. Keller has been a faithful supporter of our developmental and commercial efforts in the United States, and he has witnessed the dramatic benefits enjoyed by our customers. We are pleased that he has offered to bring the benefits of Lifeline to the people of UAE.

"In choosing Dr. McIsaac and his marketing team, we believe we will be able to rapidly grow sales and better serve the Australia and New Zealand markets. Dr. McIsaac brings a wealth of experience in direct to consumer sales and marketing. Together these agreements are a key part of our strategy to internationalize our brand."

Lifeline® Skin Care is the only skin care line that is based on human parthenogenetic stem cells that stimulate your skin's own abilities to repair itself. Lifeline products are sold in pairs, including a day cream and a night cream. A complete set is sufficient for one month of regular use.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements
Statements pertaining to anticipated developments, potential sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20111110005408r1&sid=14230&distro=ftp
International Stem Cell Corporation
Kenneth C. Aldrich, Co-Chairman
760-940-6383
kaldrich@intlstemcell.com

or
International Stem Cell Corporation
Donna Queen, Vice President of Marketing and Business Development
760-710-3295
dqueen@lifelineskincare.com
or
Lippert/Heilshorn & Associates
Don Markley, 310-691-7100
dmarkley@lhai.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cell Therapy | Comments Off on International Stem Cell Corporation Announces the Launch of Two New International Sales Initiatives for Lifeline Skin Care